Skip to main content
. Author manuscript; available in PMC: 2022 Nov 4.
Published in final edited form as: Lancet Oncol. 2022 May;23(5):570–572. doi: 10.1016/S1470-2045(22)00155-3

Figure: Overall survival.

Figure:

Overall survival for ACCL0431 participants with disseminated cancer randomly assigned to observation or treatment with sodium thiosulfate with median follow-up of 3.5 years (A; log rank p=0.0090) and with a median follow-up of 7·8 years (B; log rank p=0.040). In panel B, in the observation group at year 2, there is one patient whose classification was changed from at-risk to censored due to not providing written informed consent for continued use of data beyond the age of 18 years.